儿童急性B淋巴细胞白血病缓解期外周血MDSCs的变化及意义

doi:10.3969/j.issn.1004-616x.2015.06.010

Abstract

Abstract: OBJECTIVE: To investigate the changes,pofential role and cliniral significance of myeloid derived suppressor cells(MDSCs) in the peripheral blood of pediatric patients with B-lineage acute lymphoblastic leukemia(BALL) during remission. METHODS: 22 patients with B-ALL from our hospital treated by VDLP chemotherapy regimen including vincristine,daunorubicin,L-asparaginase and prednisone were selected as the test group during remission,and 20 cases of healthy children were also selected as control group(age and gender-matched). Peripheral blood(PB) were obtained frompatients and controls. Changes of CD33⁺ cells,CD33⁺HLA-DR^- cells,CD14⁺CD33⁺HLADR^- MDSCs and CD15⁺CD33⁺HLA-DR^- MDSCs were examined by flow cytometry,and analyzed statistically wie software of GraphPad Prisms. RESULTS: We found no change of CD33⁺ cells between the patients and control group. However,the ratio of CD33⁺HLA-DR^-/CD33⁺ cells in the patients with B-ALL during remission was lower than that in the healthy control group(P=0.001). The ratio of boe monocyte derived CD14⁺CD33⁺HLA-DR^- MDSCs(P=0.001) and CD15⁺CD33⁺HLA-DR^- MDSCs derived from granulocytes were lower in the healthy control group(P=0.004). CONCLUSION: MDSCs in pediatric patients with B-ALL treated by VDLP regimen during remission was often lower when compared to healthy control,the low level of MDSCs in B-ALL may be associated wie normal immunological system not recovered completely in the remission phase.

Key words: leukemia, acute leukemia, B-ALL, chemotherapy, myeloid derived suppressor cells

CLC Number:

R733.7

XIONG Shudao, WANG Huiping, PU Lianfang, HU Linhui, ZHANG Cui, YANG Dongdong, ZHAI Zhimin. The change of MDSCs and its clinical significance in childhood B-lineage acute lymphoblastic leukemia during remission[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(6): 454-458.

References

[1] Cavassani KA,Carson WF,Moreira AP,et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth[J]. Blood,2010,115(22):4403-4411.
[2] Raychaudhuri B,Rayman P,Ireland J,et al. Myeloidderived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma[J]. Neuro Oncol,2011, 13(6):591-599.
[3] Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy[J]. Clin Cancer Res, 2007,13(18 Sup 1):5243-5248.
[4] Gabrilovich DI,Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol,2009, 9(3):162-174.
[5] Bronte V,Serafini P,Apolloni E,Zanovello P. Tumorinduced immune dysfunctions caused by myeloid suppressor cells[J]. J Immunother,2001,24(6):431-446.
[6] Albeituni SH,Ding C,Yan J. Hampering immune suppressors:therapeutic targeting of myeloid-derived suppressor cells in cancer[J]. Cancer J,2013,19(6):490-501.
[7] Almand B,Clark JI,Nikitina E,et al. Increased production of immature myeloid cells in cancer patients:a mechanism of immunosuppression in cancer[J]. J Immunol,2001,166(1):678-689.
[8] Filipazzi P,Huber V,Rivoltini L. Phenotype,function and clinical implications of myeloid-derived suppressor cells in cancer patients[J]. Cancer Immunol Immunother,2012,61(2):255-263.
[9] Nagaraj S,Youn JI,Weber H,et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer[J]. Clin Cancer Res, 2010,16(6):1812-1823.
[10] Zhang H,Maric I,DiPrima MJ,et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer[J]. Blood,2013,122(7):1105-1113.
[11] Lin Y,Gustafson MP,Bulur PA,et al. Immunosuppressive CD14⁺HLA-DR^low/- monocytes in B-cell non-Hodgkin lymphoma[J]. Blood,2011,117(3):872-8781.
[12] Sander LE,Sackett SD,Dierssen U,et al. Hepatic acutephase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function[J]. J Exp Med,2010,207(7):1453-1464.
[13] Ko JS,Rayman P,Ireland J,et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained[J]. Cancer Res, 2010,70(9):3526-3536.
[14] Montero AJ,Diaz-Montero CM,Kyriakopoulos CE,et al. Myeloid-derived suppressor cells in cancer patients:a clinical perspective[J]. J Immunother,2012,35(2):107-115.
[15] Gorgun GT,Whitehill G,Anderson JL,et al. Tumorpromoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans[J]. Blood,2013,121(15):2975-2987.
[16] Chen MF,Kuan FC,Yen TC,et al. IL-6-stimulated CD11b⁺ CD14⁺HLA-DR^- myeloid-derived suppressor cells,are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus[J]. Oncotarget,2014,5(18):8716-8728.
[17] Rudolph BM,Loquai C,Gerwe A,et al. Increased frequencies of CD11b⁺CD33⁺CD14⁺HLA-DR^low myeloid-derived suppressor cells are an early event in melanoma patients[J]. Exp Dermatol,2014,23(3):202-204.
[18] Huang A,Zhang B,Wang B,et al. Increased CD14⁺HLA-DR^-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients[J]. Cancer Immunol Immunother,2013, 62(9):1439-1451.
[19] Khaled YS,Ammori BJ,Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients[J]. J Immunol Res,2014,2014:879897.
[20] Wang Z,Zhang L,Wang H,et al. Tumor-induced CD14⁺HLA-DR^-/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients[J]. Cancer Immunol Immunother, 2015, 64(3):389-399.
[21] Alizadeh D1,Trad M,Hanke NT,et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer[J].Cancer Res,2014,74(1):104-118.
[22] Cripps JG,Gorham JD. MDSC in autoimmunity[J]. Int Immunopharmacol,2011,11(7):789-793.

The change of MDSCs and its clinical significance in childhood B-lineage acute lymphoblastic leukemia during remission

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XU Qilu, GAO Hui, RAN Xuehong, WANG Junjun, ZHANG Junying, LIU Liping. Gene mutation and clinical correlation analyses of myeloid leukemia with abnormal karyotypes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 296-301,306.
[2]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[3]	TIAN Wei, FANG Yan, WU Hantian, JI Buqiang, XIA Zhaolin. Expressions and activities of lncRNAs and mRNAs in acute myeloid leukemia [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 110-115.
[4]	FU Qiong, TANG Wenjuan, CHENG Yong, HE Renzheng, LIANG Bing. Induction of differentiation of K652 leukemia cells by Herba Saginae Japonicae [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 37-41.
[5]	TANG Wenjuan, FU Qiong, CHENG Yong, LUO Shicheng, LIANG Bing. Induction of differentiation of human acute promyelocytic leukemia cells by an ethanol extract from Herba Saginae Japonicae [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 42-47.
[6]	WAN Shuquan, WEI Lijun, WANG Fuhua, ZENG Yong. Expression of miR-200b-3p and PAK2 in chemotherapy-resistant and sensitive ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 216-221.
[7]	YANG Jinru, QIN Lulu, ZHU Yongfei. Meta analysis on association between JAK2 gene mutation and susceptibility to chronic myeloid leukemia [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 231-237.
[8]	GUO Xiao, WANG Rui, WU Juan, JI Xiaokun, WANG Heng, ZHANG Yan, MA Yang, DU Yun. Significance of EGFR gene mutation in fresh cytological specimens of lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(1): 67-70.
[9]	HE Shuzhi, ZHAO Yue, LIU Yang, YANG Liucai, CHEN Ping, LIU Ran. Evaluation of the quality of life among esophageal cancer patients who received chemotherapy [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 437-444,449.
[10]	YANG Xingxiao, MA Ming, SHAN Baoen, LI Youmei, SONG Heng, LIU Zhikun, ZHU Shuchai. Effect of cinobufacini on chemotherapy sensitivity and toxicity of human esophageal carcinoma cells in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 96-101.
[11]	WU Huatao, SHEN Jiaxin, LIU Jing. Overexpression of Notch3 enhance the efficacy of cisplatin to MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 111-114,120.
[12]	QIN Xu-jun，HE Wei，HAI Chun-xu*. Role of protein Bcl-2 in the oxidative injury induced by radiotherapy or chemotherapy [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(5): 361-364.
[13]	ZHANG Xiao-ping1，JIAN Zi-ying1，CHEN Bao-an，XU Pei-pei，PENG Miao-xin，XIA Guo-hua，CHENG Lu，LU Zu-hong. Detection of SNPs of DCK and CDA genes in five leukemia cell lines with MALDI-TOF MS [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(2): 115-119.
[14]	ZHAO Min，WANG Xiao-hua，LI Tie-chen，ZHAO Yue-hua*. Analysis of mutation in the juxtamembrane domain of Flt3 gene in leukemia [J]. , 2011, 23(4): 294-297.
[15]	XIAO Hui1,ZHANG Yue-ming1,GU Dan-tian2,HU-Han hua3. Effect of Pleurotas Sapidus Extract on 5-Fu Chemotherapeutic Function [J]. , 2007, 19(1): 59-063.